Neovasc's Tiara™ Program for the Transcatheter Treatment of Mitral Valve Disease Will Be Featured in Two Sessions
VANCOUVER, Oct. 24, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that researchers will present data on the company's Tiara™ transcatheter mitral valve in preclinical development for the treatment of mitral valve disease at the upcoming 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
Alexei Marko, CEO of Neovasc, commented, "The annual TCT conference is the leading scientific forum for interventional cardiology and we look forward to the opportunity to share our successful preclinical Tiara experience with cardiovascular opinion leaders from around the world, as we plan for the first-in-human Tiara studies we are targeting for early 2014."
The Tiara program is a novel solution to treat mitral valve regurgitation, a serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy. Mitral regurgitation is often severe and can lead to heart failure and death, but conventional surgical treatments are only appropriate for a small percentage of patients. Approximately four million individuals in the US alone are estimated to have mitral disease.
The Neovasc TCT 2013 presentations include the following:
Session Vlll: Next Generation Mitral Valve Therapies - Part 2
Transcatheter Mitral Valve Replacement
Neovasc Tiara Program Update
Monday, Oct. 28, 3:35pm PT
Edited Cases ii
Tiara Mitral Valve Implantation
(Recorded presentation of implantation procedure in animal model)
Thursday, Oct. 31, 10:30am PT
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field. TCT 2013 is being held October 27- November 1, 2013 in San Francisco, CA. For more information, visit http://www.tctconference.com/.
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. For more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.
SOURCE Neovasc Inc.